The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. While patients treated with osimertinib show clinical benefit, disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Criscione, Steven W., Martin, Matthew J., Oien, Derek B., Gorthi, Aparna, Miragaia, Ricardo J., Zhang, Jingwen, Chen, Huawei, Karl, Daniel L., Mendler, Kerrin, Markovets, Aleksandra, Gagrica, Sladjana, Delpuech, Oona, Dry, Jonathan R., Grondine, Michael, Hattersley, Maureen M., Urosevic, Jelena, Floc’h, Nicolas, Drew, Lisa, Yao, Yi, Smith, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794691/
https://www.ncbi.nlm.nih.gov/pubmed/36575215
http://dx.doi.org/10.1038/s41698-022-00337-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794691/
https://www.ncbi.nlm.nih.gov/pubmed/36575215
http://dx.doi.org/10.1038/s41698-022-00337-w

Ejemplares similares